Denali Therapeutics climbs after US FDA approves co's genetic disorder therapy

Denali Therapeutics

25/03/2026 16:09

** Shares of Denali Therapeutics DNLI.O up 3.6% at $21.72 after the U.S. Food and Drug Administration approves co's treatment for a rare genetic disorder

** Marketed as Avlayah, the enzyme replacement therapy is aimed at treating Hunter syndrome

** Hunter syndrome is caused by lack of the iduronate‑2‑sulfatase enzyme, which leads to buildup of certain sugar molecules in the brain and the body

** Avlayah is designed to replace the missing enzyme and address underlying disease progression

** Approval marks the first regulatory clearance in the U.S. for DNLI

** Including session moves, DNLI stock up 32.4% YTD, following a 18.9% drop in 2025

 (Reporting by Tharuniyaa Lakshmi in Bengaluru)

 ((tharuniyaa@thomsonreuters.com))